Alkermes Pharma Ireland

Company snapshot

Georgianna Harris leads the regulatory affairs department at Alkermes. In this role, Dr. Harris provides regulatory strategy and guidance for development candidates and commercial products. Prior to joining Alkermes, Dr. Harris spent 25 years at Merck, in positions of increasing responsibility spanning laboratory research and regulatory affairs. During her tenure with Merck’s regulatory affairs or

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Alkermes Pharma Ireland. Not investment advice.

• What is Alkermes Pharma Ireland?

  Alkermes Pharma Ireland is a pharma organization headquartered in Dublin, IE. Primary therapeutic focus areas include Schizophrenia, Narcolepsy Type 1, Narcolepsy Type 2, Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia, Idiopathic Hypersomnia (IH). NovaPharmaNews links 6 cli

• Is Alkermes Pharma Ireland publicly traded?

  Alkermes Pharma Ireland appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Alkermes Pharma Ireland develop or market?

  We link 3 drug profile(s) where Alkermes Pharma Ireland is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/alkermes-pharma-ireland#company-drugs.

• What are the latest developments for Alkermes Pharma Ireland?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Alkermes Pharma Ireland focus on?

  Alkermes Pharma Ireland focuses on Schizophrenia, Narcolepsy Type 1, Narcolepsy Type 2 based on our analysis of their pipeline programs and drug development activities.